login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MIRUM PHARMACEUTICALS INC (MIRM) Stock News
USA
- NASDAQ:MIRM -
US6047491013
-
Common Stock
69.94
USD
+0.23 (+0.33%)
Last: 11/11/2025, 10:52:05 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MIRM Latest News, Press Relases and Analysis
All
Press Releases
15 hours ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 days ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
6 days ago - By: Zacks Investment Research
- Mentions:
ANIP
NTLA
ARQT
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
6 days ago - By: Benzinga
What Analysts Are Saying About Mirum Pharmaceuticals Stock
7 days ago - By: Zacks Investment Research
- Mentions:
GLUE
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
7 days ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
7 days ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
8 days ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
13 days ago - By: Zacks Investment Research
- Mentions:
TECH
Techne (TECH) Reports Next Week: What to Know Ahead of the Release
14 days ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
a month ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
3 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
3 months ago - By: Yahoo Finance
- Mentions:
MS
CMI
HSBC
LINE
...
Arm initiated, Adobe downgraded: Wall Street's top analyst calls
3 months ago - By: Zacks Investment Research
- Mentions:
TCRX
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
4 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Yahoo Finance
- Mentions:
CBRL
EAT
GES
GOOS
...
UK's Thames Water set for over $13.5 billion rescue deal by Silver Point and Elliott, Bloomberg News reports
5 months ago - By: Zacks Investment Research
- Mentions:
MRNA
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
6 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
6 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
6 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Please enable JavaScript to continue using this application.